Quarterly report pursuant to Section 13 or 15(d)

7. STOCKHOLDERS' EQUITY (Details 2)

v3.19.1
7. STOCKHOLDERS' EQUITY (Details 2) - USD ($)
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Total stock-based compensation expense $ 637,263 $ 514,784
Research and development    
Total stock-based compensation expense 86,523 78,305
Plasma centers    
Total stock-based compensation expense 11,540 7,086
Selling, general and administrative    
Total stock-based compensation expense 498,471 394,858
Cost of goods sold    
Total stock-based compensation expense $ 40,729 $ 34,535